中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
11期
1566-1567
,共2页
癌,非小细胞肺%培美曲塞%多西他赛%疗效%不良反应
癌,非小細胞肺%培美麯塞%多西他賽%療效%不良反應
암,비소세포폐%배미곡새%다서타새%료효%불량반응
Carcinoma,non-small cell lung%Pemetrexed%Docetaxel%Curative effect%Adverse reaction
目的 观察培美曲塞和多西他赛分别联合顺铂治疗非小细胞肺癌(NSCLC)的临床疗效及不良反应发生情况.方法 共纳入NSCLC患者54例.培美曲塞组28例,接受培美曲塞500～600 mg/m2+顺铂75 mg/m2治疗,第1天.多西他赛组26例,给予多西他赛70 ～ 80 mg/m2+顺铂75 mg/m2治疗,第1天.2组均应用地塞米松预防过敏.3周为1个化疗周期,化疗3个周期.观察化疗期间疗效及药物不良反应.结果 培美曲塞组患者部分缓解10例(35.7％),稳定14例(50.0％),进展4例(14.3％),客观缓解率为35.7％,疾病控制率为85.7％.多西他赛组部分缓解9例(34.6％),稳定13例(50.0％),进展4例(15.4％),客观缓解率为34.6％,疾病控制率为84.6％.2组药物客观缓解率和疾病控制率差异无统计学意义(均P ＞0.05).多西他赛组血液毒性和脱发发生率明显高于培美曲塞组[分别为65.4％ (17/26)比50.0％(14/28),23.1％(6/26)比0.0；均P＜0.05].结论 培美曲塞联合顺铂与多西他赛联合顺铂治疗NSCLC近期疗效相似,但培美曲塞不良反应更小.
目的 觀察培美麯塞和多西他賽分彆聯閤順鉑治療非小細胞肺癌(NSCLC)的臨床療效及不良反應髮生情況.方法 共納入NSCLC患者54例.培美麯塞組28例,接受培美麯塞500～600 mg/m2+順鉑75 mg/m2治療,第1天.多西他賽組26例,給予多西他賽70 ～ 80 mg/m2+順鉑75 mg/m2治療,第1天.2組均應用地塞米鬆預防過敏.3週為1箇化療週期,化療3箇週期.觀察化療期間療效及藥物不良反應.結果 培美麯塞組患者部分緩解10例(35.7％),穩定14例(50.0％),進展4例(14.3％),客觀緩解率為35.7％,疾病控製率為85.7％.多西他賽組部分緩解9例(34.6％),穩定13例(50.0％),進展4例(15.4％),客觀緩解率為34.6％,疾病控製率為84.6％.2組藥物客觀緩解率和疾病控製率差異無統計學意義(均P ＞0.05).多西他賽組血液毒性和脫髮髮生率明顯高于培美麯塞組[分彆為65.4％ (17/26)比50.0％(14/28),23.1％(6/26)比0.0；均P＜0.05].結論 培美麯塞聯閤順鉑與多西他賽聯閤順鉑治療NSCLC近期療效相似,但培美麯塞不良反應更小.
목적 관찰배미곡새화다서타새분별연합순박치료비소세포폐암(NSCLC)적림상료효급불량반응발생정황.방법 공납입NSCLC환자54례.배미곡새조28례,접수배미곡새500～600 mg/m2+순박75 mg/m2치료,제1천.다서타새조26례,급여다서타새70 ～ 80 mg/m2+순박75 mg/m2치료,제1천.2조균응용지새미송예방과민.3주위1개화료주기,화료3개주기.관찰화료기간료효급약물불량반응.결과 배미곡새조환자부분완해10례(35.7％),은정14례(50.0％),진전4례(14.3％),객관완해솔위35.7％,질병공제솔위85.7％.다서타새조부분완해9례(34.6％),은정13례(50.0％),진전4례(15.4％),객관완해솔위34.6％,질병공제솔위84.6％.2조약물객관완해솔화질병공제솔차이무통계학의의(균P ＞0.05).다서타새조혈액독성화탈발발생솔명현고우배미곡새조[분별위65.4％ (17/26)비50.0％(14/28),23.1％(6/26)비0.0；균P＜0.05].결론 배미곡새연합순박여다서타새연합순박치료NSCLC근기료효상사,단배미곡새불량반응경소.
Objective To compare the efficacy and toxicity of pemetrexed ordocetaxel plus cisplatin in treatment of patients with non-small cell lung cancer (NSCLC).Methods All 54 patients with NSCLC were enrolled in the study.The pemetrexed group (n =28) were treated with pemetrexed (500-600 mg/m2) combined cisplatin (75 mg/m2d1).The docetaxel group (n =26) were treated with docetaxel (70-80 mg/m2) combined with cisplatin (75 mg/m2d1).Both groups were given dexamethasone to prevent allergy.Twenty-one days were acted as one course,and the effect was evaluated after at least two courses.Results The remission rate and disease control rate in pemetrexed group and docetaxel group were 35.7％ (10/28),85.7％ (24/28) and 34.6％ (9/26),84.6％(22/26) respectively (P ＞ 0.05).The side effect (hematologic toxicity and alopecia) incidence rate in the pemetrexed group was significantly lower than that in the docetaxel group [50.0％ (14/28) vs 65.4％ (17/26),0 vs 23.1％ (6/26),all P ＜ 0.05].Conclusion The efficacy of pemetrexed combined cisplatin and cocetaxel combined csplatin for the treatment of NSCLC patients have no significant difference,while the side effect incidence rate shows significant difference.
